Global Transplantation Market - 2022-2029

Global Transplantation Market - 2022-2029
Market Overview

Transplantation Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 9.2% during the forecast period (2022-2029).

A transplant, also known as a graft or an organ transplant, is a portion of tissue or an entire organ removed from its natural site and transferred to a new position in the same person or a different person. Transplants such as liver transplants can save lives. They can also restore function to improve quality of life. Moreover, transplanting the clear tissue that covers the eye (cornea) is not necessary for life but can restore sight.

Market Dynamics

Increasing clinical trials to know the accurate and tailored Care Plan before kidney transplantation is expected to drive market growth.

Every year, tens of thousands of people worldwide undergo kidney transplants, with many more on the waiting list. However, the chance of rejection remains unpredictable even after the organ has been transplanted. Verici Dx is currently verifying its technique, which uses artificial intelligence to develop RNA signatures that correlate with injury, rejection, or graft failure, in a clinical trial in the United States and Europe. Clinicians collect blood samples from kidney transplant patients at various intervals before and after the transplant and use the Illumina NextSe 2000 to analyze their transcriptome. Verici Dx is storing its RNA sequencing results, processing sequencing data, and interpreting the datasets using Illumina Connected Analytics (ICA), a secure genomic data platform implemented on the Amazon Web Services (AWS) cloud.

Moreover, Verici Dx can analyze big datasets while running a machine learning algorithm across samples using ICA. The system assists in parsing gene signatures that indicate if patients are at high risk of rejection, allowing for a more customized approach to immunosuppressant therapy following a transplant. The findings of the tests ultimately assist medics in determining how aggressive or benign a patient's immune system is even before the transplant is performed. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with transplantation are expected to hamper the market growth.

Transplant patients are at a greater risk of infection because of the need for immunosuppression, which weakens their immune system and ability to fight infection. Immunosuppressive regimens are crucial in managing organ rejection. Still, they also make patients more susceptible to certain infections. Cytomegalovirus (CMV) is a primary source of transplant-transmitted infections, affecting 60-100 percent of adults following transplantation. BK virus (BKV), Epstein-Barr virus (EBV), Herpes Simplex Virus (HSV), Varicella Zoster Virus (VZV), Toxoplasma gondii (Toxo), human Adenovirus (hADV), and, more recently, SARS-CoV-2 are among the other prominent infections. It is due to the increasing demand for organs and stems cells. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The transplantation market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, reimbursement scenario, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Patients with end-stage organ illness benefit greatly from solid organ transplantation, including longer survival and a higher quality of life. Despite the critical need for many waitlisted patients worldwide to get transplants, preliminary statistics indicate that transplantation procedures have been significantly reduced in several countries since the COVID-19 outbreak. Importantly, decreased donations and the pressure of limited resources placed on health care by the pandemic disrupted transplant systems. For instance, a review of United Network for Organ Sharing (UNOS) data in the United States comparing monthly transplants in January and February 2020 with those done in April 2020 revealed a 35.9 percent decline in organs transferred.

In addition, other factors influencing transplantation included a lack of resources (beds, surgical suites, ventilators, blood products, and renal replacement therapies) and manpower due to COVID-19 demands in the area. Surveys also demonstrated a reluctance to admit stable transplant candidates to hospitals where they could be exposed to SARS-CoV-2, and the pandemic interrupts the supply chain and process. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Tissue Products segment is expected to hold the largest market share in transplantation market

The tissue products segment is expected to dominate in 2021. Increasing prevalence in diabetes, cancer, cardiovascular disease, renal disease, new product launches by the key market players and high adoption of progressive products, including Chondrofix Osteochondral Allograft, DeNovo NT Graft, and DuraMatrix Collagen Dura Substitute Membrane, are some of the factors the market is expected to boost in the forecast period. For instance, according to the World Cancer Research Fund International, In 2020, there will be 18,094,716 million cancer diagnoses worldwide. In 2020, the age-standardized rate for all cancers (excluding non-melanoma skin cancer) for men and women combined was 190 per 100,000. Men had a greater rate than women (206.9 per 100,000). (178.1 per 100,000). Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an anticipated 2.3 million new cases (11.7 percent), followed by lung (11.4 percent), colorectal (10.0 percent), prostate (7.3 percent), and stomach (5.6 percent) cancers. Therefore, it has put a vast population in danger of irreparable tissue damage, necessitating a growing demand for tissue transplantation, fuelling category revenue growth. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global transplantation market

In 2021, North America accounted for the highest revenue share. Increasing prevalence of diabetes, cancer, cardiovascular disease, renal disease, well-developed healthcare facilities, and product launches acquisitions and increasing clinical trials by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Kidney disease is more common in women (14%) than men (12%). But for every 2 women who develop end-stage kidney disease (ESKD), 3 men's kidneys fail. Kidney disease is a leading cause of death in the U.S. 1 in 3 adults in the U.S. (approximately 80 million) is at risk for kidney disease. Therefore, it has increased the demand for transplantation.

Moreover, On June 28, 2022, Veloxis Pharmaceuticals, an Ashai Kasei company, announced that its partner, Xenikos, had dosed the first patient in a global pivotal Phase 3 clinical study designed to compare T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic (allo-HSCT). T-Guard is being developed by Xenikos B.V., a privately held biotechnology business that creates novel immunotherapies for treating patients with severe immunological illness and post-transplant rejection. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the transplantation market are Veloxis Pharmaceuticals, Inc. , Abbott, Becton Dickinson and Company, bioMérieux SA, CareDx, Inc., Hologic, Inc, QIAGEN, XVIVO, Novartis Pharmaceuticals Corporation, Genentech, Organ Recovery Systems, Bridge to Life Ltd.

Veloxis Pharmaceuticals, Inc..:

Overview:

Veloxis Pharmaceuticals is a commercial-stage specialty pharmaceutical company. It develops products and technology to improve the lives of transplant patients. The firm's products and technology include Envarsus XR and meltdose technology. The company is focused on directly commercializing its products in the United States, expanding partnerships for markets globally, and acquiring assets utilized in transplant patients and by adjacent medical supplies. Geographically, the company operates in the United States, Europe and Other countries, of which key revenue is derived from the United States.

Product Portfolio:

ENVARSUS XR (tacrolimus extended-release tablets): ENVARSUS XR is also indicated for preventing organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants.

The global transplantation market report would provide an access to an approx. 45+market data table, 40+figures and 170pages.